| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 27 | 32.8x | 17.8x | Bottom tier | |
Growth | 43 | 7.2% | 7.1% | Around median | |
Quality | 64 | 8.0% | 4.5% | Around median | |
Safety | 61 | 3.9x | 2.6x | Around median | |
Capital Return | 39 | 0.30% | 2.12% | Bottom tier | |
Momentum | 83 | 20.6% | 2.9% | Top tier | |
Sentiment | 42 | 14 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Thermo Fisher Scientific operates through four interconnected segments serving scientific research, drug development, diagnostics, and bioproduction: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. It generates revenue from the sale of analytical instruments such as Orbitrap spectrometers, consumables and bioproduction platforms, diagnostic products, as well as clinical research and drug development services; pharmaceutical and biotechnology markets account for approximately 60% of its revenue.
In Q2 FY2026, revenue increased 10% to $11.99 billion, including 5% organic growth and a 5% contribution from acquisitions, while net income according to EDGAR was approximately $1.7 billion and GAAP EPS was $4.68. Adjusted operating income increased 15% to $2.73 billion and adjusted EPS rose 13% to $6.03, with adjusted operating margin expanding 90 basis points to 22.8% and adjusted gross margin reaching 41.4%.
Growth was broad-based in Q2 FY2026: reported revenue for Life Sciences Solutions increased 13% with an adjusted operating margin of 37.0%, Analytical Instruments grew 7% with a margin of 23.0%, Specialty Diagnostics increased 6% with a margin of 27.7%, and Laboratory Products and Biopharma Services rose 12% with a margin of 14.0%. FY2025 revenue was approximately $44.6 billion and net income was $6.7 billion, compared with trailing twelve-month revenue of $46.3 billion and net income of $7.0 billion according to the latest filed EDGAR data.
The analyst consensus rates TMO shares a “Buy,” with an average price target of $597.67 and a wide range between $520 and $650, a $130 spread reflecting meaningful differences in estimates of future results. The average target is below the 52-week high of $643.99 and above the low of $435.27, while the raised FY2026 outlook and the biopharmaceutical recovery are balanced against the risks of $42.5 billion in debt and expected organic growth moderating to approximately 4%.
Figures in the text are as of 2026-08-26; the live price is shown at the top of the page.
Revenue increased 10% to $11.99 billion, driven by 5% organic growth and a 5% contribution from acquisitions. Bioproduction, clinical research, and the Research and Safety Market channel led the improvement in pharmaceuticals and biotechnology, while Electron Microscopy supported the performance of analytical instruments. Adjusted EPS reached $6.03, up 13%, with adjusted operating margin expanding to 22.8%.
The company expects revenue of between $47.4 billion and $48.1 billion, representing reported growth of between 6% and 8% compared with FY2025. It expects organic growth at the high end of the 3%–4% range, with approximately 4% in the second half of FY2026. It also raised its adjusted EPS range to $24.93–$25.33, representing growth of between 9% and 11%.
Thermo Fisher completed the acquisition of Clario in late March 2026, adding digital endpoint data solutions serving drug development and clinical research. On July 23, 2026, management said Clario’s first full quarter of ownership showed strong performance in authorizations, revenue, and earnings, and that business integration was progressing smoothly. The company expects the acquisitions together to contribute $1.6 billion in revenue and $0.32 in adjusted EPS in FY2026.
Automated analysis for informational purposes only — not investment advice.
Thermo Fisher completed the sale of the unit to Astorg for $1.1 billion in cash on August 13, 2026, as part of active portfolio management and capital reallocation. The unit had generated revenue of $645 million in FY2025, with 2% growth, and Thermo Fisher will retain a sales channel relationship for some of its products. The company expects a negative impact of approximately $200 million on FY2026 revenue and approximately $0.05 on adjusted EPS, with dilution of approximately $0.15 in the first full fiscal year after closing.
In Q2 FY2026, the company launched the Thermo Scientific Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers, along with the Vanquish Amplify UHPLC system. It also launched the Applied Biosystems PowerFlex thermal cycling platform and AI-powered software solutions to accelerate proteomics research and improve workflows. These launches coincided with 7% organic growth in Analytical Instruments and expansion of its adjusted operating margin to 23.0%.
Total debt was $42.5 billion at the end of Q2 FY2026, versus $4.1 billion in cash and cash equivalents, increasing the importance of acquisition execution and cash flow generation. Approximately 60% of revenue also depends on pharmaceuticals and biotechnology, while management did not yet consider the academic and government improvement a stable trend. The sale of the microbiology unit adds a dilutive impact on earnings, while the range of analyst targets between $520 and $650 indicates considerable variation in the assessment of these risks.
